Stocktoria
Rani Therapeutics Holdings, Inc. RANI
Rani Therapeutics Holdings, Inc. (RANI) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.6M at a -1817.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.693 |
| Retained earnings / assets | -2.262 |
| EBIT / assets | -0.654 |
| Equity / liabilities | 2.426 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
FAQ
Is RANI financially healthy?
Rani Therapeutics Holdings, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RANI pay a dividend?
No, Rani Therapeutics Holdings, Inc. does not currently pay a dividend.
How profitable is RANI?
In FY2025, Rani Therapeutics Holdings, Inc. had a net margin of -1817.1% and a return on equity of -71.5%.
What is the analyst price target for RANI?
The average Wall-Street price target for Rani Therapeutics Holdings, Inc. is $7.50, about 834.2% above the recent price, from 4 analysts.
Is RANI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Rani Therapeutics Holdings, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.